Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
BiVACOR logo — Replacing hearts. Restoring lives.

BiVACOR

Replacing hearts. Restoring lives.

Founded 2008 United States Huntington Beach, United States 46 employees Grant Total: $53.00M Life Sciences, Manufacturing +1

General Information

Company Name BiVACOR
Founded Year 2008
Location United States Huntington Beach, United States
Founders / Decision Makers
Team member
Employees 46
Industries Life Sciences, Manufacturing, Medical Devices
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with BiVACOR. To contact BiVACOR, visit bivacor.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does BiVACOR compare?

A PDF of BiVACOR and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting BiVACOR soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About BiVACOR

BiVACOR, Inc. is a clinical-stage medical device company focused on developing a long-term therapy for patients with biventricular heart failure. Led by founder Daniel Timms, PhD, and cardiovascular surgery experts William E. Cohn, MD, and O.H. (Bud) Frazier, MD, the company's flagship product, the BiVACOR Total Artificial Heart (TAH), is undergoing an FDA-approved first-in-human Early Feasibility Study (EFS). With headquarters in Huntington Beach, California, and offices in Houston, Texas, and Gold Coast, Australia, BiVACOR is dedicated to addressing the global unmet need for end-stage heart failure patients awaiting transplant. The TAH, characterized by its small size and magnetic levitation technology, represents a significant advancement in artificial heart design, offering the potential for durable, reliable, and biocompatible heart replacement for patients in need. In its latest funding round, BiVACOR secured a $13.00M grant investment from the Medical Research Future Fund (MRFF) in February 2024. The company operates within the Life Sciences, Manufacturing, and Medical Devices industries and was founded in 2008.

Business keywords: medical device company, cardiac technology, total artificial heart, biventricular heart failure, biomedical engineering, clinical-stage, innovative technology, heart failure therapy, biotechnology startup, life-extending solution, collaborative network, cardiac surgery, biomedical engineering, innovation in healthcare

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $13.00M 1
Medical Research Future Fund (MRFF)
20 Feb 2024
Series B $18.00M 2
OneVentures Cormorant Asset Management
OneVentures, Cormorant Asset Management
02 Mar 2023
Grant $3.00M 1
National Institutes of Health
20 May 2021
Series B $19.00M 2
OneVentures Cormorant Asset Management
OneVentures, Cormorant Asset Management
20 May 2021
Venture Round Undisclosed 1
OneVentures
OneVentures
17 May 2018

BiVACOR Alternatives & Competitors

View All Alternatives
BiVACOR vs
enmodes GmbH
enmodes GmbH Germany

enmodes GmbH provides design and engineering services to medical device companies. We offer wide ran...

Venture round
20 employees
Biotechnology, Manufacturing
Compare BiVACOR vs enmodes GmbH
BiVACOR vs
StarTric
StarTric Italy

Transcatether Tricuspid Valve Repair

Seed
2 employees
Manufacturing, Medical Devices
Compare BiVACOR vs StarTric
BiVACOR vs
Field Medical
Field Medical United States

The future of cardiac pulsed field ablation

Seed
390 employees
Manufacturing, Medical Devices
View all alternatives

FAQ About BiVACOR

Replacing hearts. Restoring lives.
BiVACOR was founded in 2008.
BiVACOR is headquartered in Huntington Beach, United States.
BiVACOR operates in Life Sciences, Manufacturing and Medical Devices. Its work centres on medical device company, cardiac technology, total artificial heart and biventricular heart failure.
BiVACOR has approximately 46 employees.
BiVACOR has completed 5 funding rounds, raising a total of $53.00M. The latest funding stage is Grant.
Top alternatives and competitors to BiVACOR include enmodes GmbH, StarTric, Field Medical, CorWave, Suzhou Jiecheng Medical Technology Co., Ltd. (A Genesis Medtech Company ). These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BiVACOR and enmodes GmbH are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for BiVACOR, https://bouncewatch.com/company/bivacor-inc, updated 1 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout